Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BTAI Bioxcel Therapeutics Inc.

交易中 08-24 15:22:46 EDT

0.7650

-0.0388

-4.83%

最高0.8330	最低0.7510	成交量94.25万
今开0.8000	昨收0.8038	日振幅10.20%
总市值2,395万	流通市值2,057万	总股本3,131万
成交额74.10万	换手率3.51%	流通股本2,689万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BTAI","market":"US","secType":"STK","nameCN":"Bioxcel Therapeutics Inc.","latestPrice":0.765,"timestamp":1787599359960,"preClose":0.8038,"halted":0,"volume":942508,"delay":0,"changeRate":-0.048270714107986994,"floatShares":26889300,"shares":31305499,"eps":-3.150527,"marketStatus":"交易中","change":-0.0388,"latestTime":"08-24 15:22:46 EDT","open":0.8,"high":0.833,"low":0.751,"amount":740987.6312468001,"amplitude":0.102015,"askPrice":0.7655,"askSize":5,"bidPrice":0.765,"bidSize":1138,"shortable":3,"etf":0,"ttmEps":-3.150527,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1520485200000,"exchange":"NASDAQ","adjPreClose":0.8038,"preHourTrading":{"tag":"盘前","latestPrice":0.803,"preClose":0.8038,"latestTime":"09:25 EDT","volume":37961,"amount":30694.742256640002,"timestamp":1787577918275,"change":-0.0008,"changeRate":-0.000995,"amplitude":0.082608},"postHourTrading":{"tag":"盘后","latestPrice":0.8089,"preClose":0.8038,"latestTime":"19:47 EDT","volume":40432,"amount":32978.9299,"timestamp":1787356051256,"change":0.0051,"changeRate":0.006345,"amplitude":0.068176},"volumeRatio":0.745143,"impliedVol":0.2625,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BTAI","defaultTab":"news","newsList":[{"id":"1134489117","title":"BioXcel Therapeutics于2026年8月21日签署信贷协议第十三次修订案——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1134489117","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134489117?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:03","pubTimestamp":1787569390,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics——这家生物制药企业于2026年8月21日正式签署了信贷协议的第十三次修订案，相关细节已通过美国证券交易委员会（SEC）的公开文件对外披露。这一动态标志着公司在融资安排上的又一重要调整节点，反映出其持续优化资本结构的战略意图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123597507","title":"BioXcel Therapeutics 必须在2026年8月21日前达成协议以偿还债务或寻求替代资本方案——SEC文件揭示","url":"https://stock-news.laohu8.com/highlight/detail?id=1123597507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123597507?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:05","pubTimestamp":1786446358,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics 面临紧迫的财务时间节点。根据其向美国证券交易委员会提交的文件，该公司被要求在2026年8月21日之前，必须签署相关协议，用以偿还现有债务义务，或者积极寻求替代性的资本解决方案。这一时间限制为其财务状况蒙上了更为严峻的阴影，迫使管理层在有限窗口期内做出关键决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101607103","title":"BioXcel Therapeutics 贷款方放宽最低流动性限制：从625万美元降至300万美元——SEC文件显示","url":"https://stock-news.laohu8.com/highlight/detail?id=1101607103","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101607103?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:05","pubTimestamp":1786446326,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics 迎来关键财务调整。根据最新提交的SEC文件，其贷款方已同意将最低流动性契约要求大幅下调。具体而言，这一门槛从原先的625万美元，显著降低至300万美元。\n此举无疑为该公司提供了更灵活的财务缓冲。在生物科技领域，现金流一直是悬在企业头顶的达摩克利斯之剑。此次契约条件的放宽，意味着BioXcel Therapeutics在短期内面临的资金链压力有所缓解。它可能在当前阶段获得更多战略调整空间，以应对研发支出或市场波动。\n监管文件明确披露了这一变动。对于密切关注该公司股票表现及未来发展路径的投资者而言，这无疑是一个重要的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117292485","title":"Bioxcel Therapeutics：贷款方同意将本金还款推迟至2026年8月31日；根据SEC文件，到期应付本息合计902万美元外加应计利息","url":"https://stock-news.laohu8.com/highlight/detail?id=1117292485","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117292485?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:07","pubTimestamp":1785755227,"startTime":"0","endTime":"0","summary":"Bioxcel Therapeutics Inc.迎来关键财务进展。根据最新提交的SEC文件披露，该公司已与贷款方达成协议，将原定到期的本金还款义务推迟至2026年8月31日。这一调整意味着，届时公司需一次性支付约902万美元的本金，同时还需结清这笔债务在此期间产生的全部应计利息。此次延期协议的签署，为Bioxcel Therapeutics提供了宝贵的现金流缓冲空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154078824","title":"BioXcel Therapeutics需在2026年8月10日前达成最终协议——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1154078824","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154078824?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:04","pubTimestamp":1785755062,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics公司（股票代码：BTAI）在一份提交给美国证券交易委员会（SEC）的文件中明确表示，该公司必须在2026年8月10日之前签署并落实最终协议。这一时间节点被写入了监管文件，意味着如果未能如期完成，可能面临相应的合规后果。文件内容同时指出，该要求具有强制性，公司方面已对此作出确认。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108005693","title":"BioXcel Therapeutics在2026年ASCP年会上公布SERENITY At-Home 3期试验新数据，针对双相情感障碍或精神分裂症相关激越","url":"https://stock-news.laohu8.com/highlight/detail?id=1108005693","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108005693?lang=zh_cn&edition=full","pubTime":"2026-05-28 19:02","pubTimestamp":1779966152,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc. 于2026年美国临床精神药理学会年会上，公布了其SERENITY At-Home 3期临床试验的新数据。该试验旨在评估其疗法对与双相情感障碍或精神分裂症相关的急性激越的疗效与安全性。此次公布的数据进一步揭示了该居家给药方案在控制患者激越症状方面的潜力。这些新发现为BioXcel Therapeutics的核心产品线提供了重要支持，特别是在满足精神健康领域对有效且便捷的急性干预措施的迫切需求方面。公司表示，这些数据将有助于推进该疗法的后续监管沟通与开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161815906","title":"BioXcel Therapeutics Inc：FDA为Igalmi新药申请设定PDUFA目标审评日期为2026年11月14日——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1161815906","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161815906?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:00","pubTimestamp":1775041218,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件披露，BioXcel Therapeutics Inc. 已获得美国食品药品监督管理局（FDA）就其Igalmi新药申请设定的处方药使用者付费法案（PDUFA）目标审评日期。该关键日期定于2026年11月14日，标志着监管机构完成审评的最后期限。\n这一进展为该公司针对Igalmi的审批路径提供了明确的时间表，是药物研发过程中的一个重要监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176205883","title":"BioXcel Therapeutics宣布FDA受理Igalmi®居家使用补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176205883","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176205883?lang=zh_cn&edition=full","pubTime":"2026-04-01 19:00","pubTimestamp":1775041216,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc. (BTAI) 近日宣布，美国食品药品监督管理局（FDA）已正式受理其旗下药物Igalmi®用于居家环境的补充新药申请（sNDA）。这一进展标志着该药物在拓展临床应用场景方面迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186310919","title":"BioXcel Therapeutics股价盘前飙升21.1%，实验性阿片类药物戒断疗法中期试验显效","url":"https://stock-news.laohu8.com/highlight/detail?id=1186310919","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186310919?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:35","pubTimestamp":1772714114,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc. (BTAI) 股价在盘前交易中大幅上涨21.1%，此前该公司宣布其用于治疗阿片类药物戒断的实验性药物在一项中期临床试验中显示出积极疗效。这一积极数据显著提振了投资者信心，推动该公司股价强势上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115086186","title":"BioXcel Therapeutics Inc.：Bxcl501在治疗阿片类药物戒断症状中展现出临床获益与良好耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1115086186","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115086186?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:10","pubTimestamp":1772712603,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics Inc.公布的最新临床数据显示，其研究性药物Bxcl501在治疗阿片类药物戒断症状方面表现出显著的临床益处和良好的耐受性特征。该结果突显了该疗法在应对这一严峻公共卫生挑战方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145611771","title":"BioXcel Therapeutics公布哥伦比亚大学主导的Bxcl501治疗阿片戒断二期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145611771","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145611771?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:04","pubTimestamp":1772712277,"startTime":"0","endTime":"0","summary":"BioXcel Therapeutics宣布，由哥伦比亚大学主导的Bxcl501用于治疗阿片戒断的二期临床研究取得积极顶线结果。该研究达到了主要终点，显示Bxcl501能显著缓解戒断症状。公司计划基于这些数据与监管机构讨论后续开发路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518224141","title":"Bioxcel Therapeutics, Inc.盘中异动 大幅上涨5.34%报3.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224141","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518224141?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:34","pubTimestamp":1741613647,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时34分，Bioxcel Therapeutics, Inc.股票出现异动，股价急速拉升5.34%。截至发稿，该股报3.55美元/股，成交量10.9296万股，换手率3.52%，振幅7.57%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.01%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2096.04%、413.43%、64.56%，振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.，振幅分别为100.05%、99.13%、98.72%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021340796403690&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021340796403690&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2517165369","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘股价大跌6.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517165369","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517165369?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:33","pubTimestamp":1741271605,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时33分，Bioxcel Therapeutics, Inc.股票出现异动，股价大幅下跌6.23%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.60%。其相关个股中，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为970.92%、111.73%、51.06%，振幅较大的相关个股有Plus Therapeutics, Inc.、Entero Therapeutics Inc.、Virax Biolabs Group Limited，振幅分别为24.20%、13.23%、12.51%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223325989eb49e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223325989eb49e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BTAI"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2517948552","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘大幅拉升17.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517948552?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:30","pubTimestamp":1741185045,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时30分，Bioxcel Therapeutics, Inc.股票出现波动，股价快速上涨17.96%。截至发稿，该股报3.19美元/股，成交量444.527万股，换手率143.31%，振幅0.56%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为310.56%、251.30%、183.65%，振幅较大的相关个股有4D Molecular Therapeutics, Inc.、Plus Therapeutics, Inc.、Zura Bio Limited，振幅分别为8.56%、6.59%、5.61%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223045989d458b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223045989d458b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BTAI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516734634","title":"Bioxcel Therapeutics, Inc.股价拉升12.49% 市值涨94.14万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516734634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516734634?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012337,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Bioxcel Therapeutics, Inc.股票出现波动，股价大幅拉升12.49%。截至发稿，该股报2.43美元/股，成交量33.3719万股，换手率10.76%，振幅3.34%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.32%、27.19%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223217abe63369&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223217abe63369&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378557","title":"Bioxcel Therapeutics, Inc.股价拉升13.86% 市值涨84.68万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378557","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514378557?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753062,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Bioxcel Therapeutics, Inc.股票出现波动，股价快速拉升13.86%。截至发稿，该股报1.97美元/股，成交量1489.61万股，换手率480.24%，振幅1.14%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。其相关个股中，Tc Biopharm  Plc C/Wts 10/02/2028 、Anaptysbio, Inc.、Enveric Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.24%、239.11%、55.69%，振幅较大的相关个股有Trevi Therapeutics, Inc.、Enanta Pharmaceuticals, Inc.、Aardvark Therapeutics, Inc.，振幅分别为7.11%、6.58%、6.22%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223102abe0e9f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223102abe0e9f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BTAI","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513720455","title":"Bioxcel Therapeutics, Inc.盘中异动 早盘急速下挫5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513720455?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:55","pubTimestamp":1740408955,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时55分，Bioxcel Therapeutics, Inc.股票出现异动，股价大幅下挫5.16%。截至发稿，该股报2.02美元/股，成交量1.2261万股，换手率0.40%，振幅5.16%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Telix Pharmaceutic涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为139.12%、56.79%、25.06%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225555abdb13e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225555abdb13e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BTAI","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513220290","title":"Bioxcel Therapeutics, Inc.盘中异动 临近午盘急速下挫5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513220290","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513220290?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:47","pubTimestamp":1740156420,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时47分，Bioxcel Therapeutics, Inc.股票出现波动，股价快速跳水5.22%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.45%。其相关个股中，Osr Holdings, Inc.、Nkgen Biotech, Inc.、Invivyd, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为228.03%、157.14%、121.91%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为72.46%、57.50%、48.35%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222004700a24ecdf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222004700a24ecdf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510863618","title":"Bioxcel Therapeutics, Inc.盘中异动 快速拉升13.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510863618?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:32","pubTimestamp":1739197924,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时32分，Bioxcel Therapeutics, Inc.股票出现波动，股价急速上涨13.64%。截至发稿，该股报3.00美元/股，成交量1828股，换手率0.06%，振幅4.17%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Biodexa Pharmaceuticals Plc、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为1497.30%、838.56%、553.24%，振幅较大的相关个股有Biodexa Pharmaceuticals Plc、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.，振幅分别为12.53%、12.34%、7.48%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223204abc9a517&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223204abc9a517&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BTAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508446580","title":"Bioxcel Therapeutics, Inc.盘中异动 股价大涨5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508446580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508446580?lang=zh_cn&edition=full","pubTime":"2025-02-04 23:19","pubTimestamp":1738682372,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日23时19分，Bioxcel Therapeutics, Inc.股票出现波动，股价急速上涨5.62%。截至发稿，该股报0.325美元/股，成交量19.1574万股，换手率0.39%，振幅6.76%。Bioxcel Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.36%。其相关个股中，Azitra Inc、Evaxion Biotech As、Regulus Therapeutics Inc.涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为1472.65%、871.55%、220.40%，振幅较大的相关个股有Azitra Inc、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Viracta Therapeutics, Inc.，振幅分别为64.17%、49.87%、44.22%。Bioxcel Therapeutics, Inc.公司简介：BioXcel Therapeutics Inc 是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231933a239326d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204231933a239326d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BTAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioxceltherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.3245},{"period":"1month","weight":-0.0864},{"period":"3month","weight":-0.2887},{"period":"6month","weight":-0.488},{"period":"1year","weight":-0.8463},{"period":"ytd","weight":-0.4976}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bioxcel Therapeutics, Inc.于2017年3月29日成为特拉华州公司，为BioXcel的全资附属公司。该公司是一家利用人工智能平台开发神经科学领域变革性药物的生物制药公司。其商业产品IGALMI已获批用于治疗与精神分裂症和双相情感障碍相关的急性激越，其研发管线包括针对阿尔茨海默病激越的候选药物及免疫肿瘤学资产。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.080194},{"month":2,"riseRate":0.75,"avgChangeRate":0.207156},{"month":3,"riseRate":0.25,"avgChangeRate":-0.134633},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.031842},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.027429},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.019292},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052754},{"month":8,"riseRate":0.222222,"avgChangeRate":0.090065},{"month":9,"riseRate":0.25,"avgChangeRate":-0.149729},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023255},{"month":11,"riseRate":0.375,"avgChangeRate":0.021118},{"month":12,"riseRate":0.375,"avgChangeRate":0.097907}],"exchange":"NASDAQ","name":"Bioxcel Therapeutics Inc.","nameEN":"Bioxcel Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bioxcel Therapeutics Inc.,BTAI,Bioxcel Therapeutics Inc.股票,Bioxcel Therapeutics Inc.股票老虎,Bioxcel Therapeutics Inc.股票老虎国际,Bioxcel Therapeutics Inc.行情,Bioxcel Therapeutics Inc.股票行情,Bioxcel Therapeutics Inc.股价,Bioxcel Therapeutics Inc.股市,Bioxcel Therapeutics Inc.股票价格,Bioxcel Therapeutics Inc.股票交易,Bioxcel Therapeutics Inc.股票购买,Bioxcel Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bioxcel Therapeutics Inc.(BTAI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bioxcel Therapeutics Inc.(BTAI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}